



Seres Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference

August 1, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 1, 2019-- [Seres Therapeutics, Inc.](#) (Nasdaq: MCRB) today announced that it will present at the Canaccord Genuity 39th Annual Growth Conference in Boston, MA on Wednesday, August 7 at 8:00 a.m. ET.

A live audio webcast of the presentation will be available under the "Investors and Media" section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres' SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres' SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent *C. difficile* infection. Seres is also developing SER-401 in a Phase 1b study in patients with metastatic melanoma. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190801005078/en/>

Source: Seres Therapeutics, Inc.

Seres Therapeutics

Carlo Tanzi, Ph.D., 617-203-3467

Vice President, Investor Relations and Corporate Communications

ctanzi@serestherapeutics.com